Marcel Simis1, Felipe Fregni2, Linamara R Battistella3. 1. Neuromodulation Center, Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, MA, USA. marcelsimis@gmail.com. 2. Institute of Physical and Rehabilitation Medicine, University of Sao Paulo Medical School, Sao Paulo, Brazil. 3. Neuromodulation Center, Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, MA, USA.
Abstract
STUDY DESIGN: A randomized, sham-controlled clinical trial. OBJECTIVE: To test the effects of tDCS, combined with robotic training, on gait disability in SCI. Our hypothesis was that participants who received active tDCS would experience greater walking gains, as indexed by the WISCI-II, than those who received sham tDCS. SETTING: University of São Paulo, Brazil. METHODS: This randomized, double-blind study comprised 43 participants with incomplete SCI who underwent 30 sessions of active (n = 21) or sham (n = 22) tDCS (20 min, 2 mA) before every Lokomat session of 30 min (3 times a week over 12 weeks or 5 times a week over 6 weeks). The main outcome was the improvement in WISCI-II. Participants were assessed at baseline, after 15 and 30 sessions of Lokomat, and after three months of treatment. RESULTS: There was a significant difference in the percentage of participants that improved in WISCI-II at the 30-session, compared with baseline: 33.3% in the sham group and 70.0% in the active group (p = 0.046; OR: 3.7; 95% CI: 1.0-13.5). At the follow-up, the improvement compared with baseline in the sham group was 35.0% vs. 68.4% for the active group (p = 0.046; OR: 3.7; 95% CI: 1.0-13.5). There was no significant difference at the 15-session. CONCLUSION: Thirty sessions of active tDCS is associated with a significant improvement in walking, compared to sham. Moreover, 15 sessions had no significant effect. The improvement in WISCI-II can be related to different aspects of motor learning, including motor recovery and compensation.
STUDY DESIGN: A randomized, sham-controlled clinical trial. OBJECTIVE: To test the effects of tDCS, combined with robotic training, on gait disability in SCI. Our hypothesis was that participants who received active tDCS would experience greater walking gains, as indexed by the WISCI-II, than those who received sham tDCS. SETTING: University of São Paulo, Brazil. METHODS: This randomized, double-blind study comprised 43 participants with incomplete SCI who underwent 30 sessions of active (n = 21) or sham (n = 22) tDCS (20 min, 2 mA) before every Lokomat session of 30 min (3 times a week over 12 weeks or 5 times a week over 6 weeks). The main outcome was the improvement in WISCI-II. Participants were assessed at baseline, after 15 and 30 sessions of Lokomat, and after three months of treatment. RESULTS: There was a significant difference in the percentage of participants that improved in WISCI-II at the 30-session, compared with baseline: 33.3% in the sham group and 70.0% in the active group (p = 0.046; OR: 3.7; 95% CI: 1.0-13.5). At the follow-up, the improvement compared with baseline in the sham group was 35.0% vs. 68.4% for the active group (p = 0.046; OR: 3.7; 95% CI: 1.0-13.5). There was no significant difference at the 15-session. CONCLUSION: Thirty sessions of active tDCS is associated with a significant improvement in walking, compared to sham. Moreover, 15 sessions had no significant effect. The improvement in WISCI-II can be related to different aspects of motor learning, including motor recovery and compensation.
Authors: Michael A Nitsche; Maren S Nitsche; Cornelia C Klein; Frithjof Tergau; John C Rothwell; Walter Paulus Journal: Clin Neurophysiol Date: 2003-04 Impact factor: 3.708
Authors: Nuray Yozbatiran; Zafer Keser; Matthew Davis; Argyrios Stampas; Marcia K O'Malley; Catherine Cooper-Hay; Joel Frontera; Felipe Fregni; Gerard E Francisco Journal: NeuroRehabilitation Date: 2016-07-15 Impact factor: 2.138
Authors: Anthony S Burns; Jude J Delparte; Mary Patrick; Ralph J Marino; John F Ditunno Journal: Neurorehabil Neural Repair Date: 2011-02 Impact factor: 3.919
Authors: Rubén Hernández de Paz; Diego Serrano-Muñoz; Soraya Pérez-Nombela; Elisabeth Bravo-Esteban; Juan Avendaño-Coy; Julio Gómez-Soriano Journal: J Neuroeng Rehabil Date: 2019-09-14 Impact factor: 4.262